Department of Signals and Systems, Chalmers University of Technology, Gothenburg, Sweden.
Int J Hyperthermia. 2012;28(2):175-83. doi: 10.3109/02656736.2011.641655.
To design and test a wideband multi-channel amplifier system for time reversal (TR) microwave hyperthermia, operating in the frequency range 300 MHz-1 GHz, enabling operation in both pulsed and continuous wave regimes. This is to experimentally verify that adaptation of the heating pattern with respect to tumour size can be realised by varying the operating frequency of the antennas and potentially by using Ultra-wideband (UWB) pulse sequences instead of pure harmonic signals.
The proposed system consists of 12 identical channels driven by a common reference signal. The power and phase settings are applied with resolutions of 0.1 W and 0.1°, respectively. Using a calibration procedure, the measured output characteristics of each channel are interpolated using polynomial functions, which are then implemented into a system software algorithm driving the system feedback loop.
The maximum output power capability of the system varies with frequency, between 90 and 135 W with a relative power error of ± 6%. A phase error in the order of ± 4° has been achieved within the entire frequency band.
The developed amplifier system prototype is capable of accurate power and phase delivery, over the entire frequency band of the system. The output power of the present system allows for an experimental verification of a recently developed TR-method on phantoms or animals. The system is suitable for further development for head and neck tumours, breast or extremity applications.
设计并测试一种工作在 300MHz-1GHz 频率范围内的宽带多通道放大器系统,用于时间反转(TR)微波热疗,实现脉冲和连续波两种工作模式。通过改变天线的工作频率,以及可能采用超宽带(UWB)脉冲序列而不是纯谐波信号,来实现对肿瘤大小相关加热模式的适应性,这需要通过实验来验证。
所提出的系统由 12 个相同的通道组成,由一个公共参考信号驱动。功率和相位设置的分辨率分别为 0.1W 和 0.1°。通过校准程序,使用多项式函数对每个通道的测量输出特性进行插值,然后将这些函数实现到系统软件算法中,以驱动系统反馈回路。
系统的最大输出功率能力随频率而变化,在 90 到 135W 之间,相对功率误差为±6%。在整个频带内实现了±4°的相位误差。
所开发的放大器系统原型能够在整个系统频带内实现精确的功率和相位传输。本系统的输出功率允许在体模或动物上对最近开发的 TR 方法进行实验验证。该系统适用于头颈部肿瘤、乳房或四肢应用的进一步开发。